Forian Inc., a prominent player in data science-driven solutions for the life science, healthcare, and financial services industries, has unveiled its financial outcomes for the second quarter of 2025, revealing notable growth and operational efficiency. The company's revenue reached $7.5 million, a 56% surge from the $4.8 million reported in the corresponding quarter of the previous year. This remarkable growth is credited to strategic contract renewals, the acquisition of new clients, and the enhancement of core capabilities.
The net income for the quarter was reported at $0.2 million, or $0.01 per share, a significant turnaround from a net loss of $2.6 million, or $0.08 per share, in the prior year. Adjusted EBITDA also experienced a notable rise to $0.6 million, up from $0.1 million the previous year, highlighting the company's improved profitability and margin expansion. With cash, cash equivalents, and marketable securities totaling $35.6 million as of June 30, 2025, Forian is well-positioned for future investments and growth.
Max Wygod, CEO and Executive Chairman of Forian, reiterated the company's dedication to fostering organic growth and making strategic investments to enhance its platform and deliver value throughout the healthcare ecosystem. The company has reaffirmed its full-year 2025 outlook, projecting revenue to be in the range of $28 to $30 million and Adjusted EBITDA between ($1.0) to $1.0 million.
Forian's Q2 2025 performance underscores its capability to utilize data science and analytics to achieve operational and financial advancements. By focusing on business development, expanding its capabilities, and generating positive momentum in its markets, Forian has established itself as a significant entity in the healthcare and life sciences industries. For further details on Forian's financial results and to access the conference call discussing these outcomes, visit https://www.forian.com/investors.
